Eli Lilly and Company (NYSE:LLY) Shares Sold by Sather Financial Group Inc

Sather Financial Group Inc reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,741 shares of the company’s stock after selling 22 shares during the period. Sather Financial Group Inc’s holdings in Eli Lilly and Company were worth $1,542,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of LLY. China Universal Asset Management Co. Ltd. grew its holdings in Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after acquiring an additional 1,620 shares during the period. Acadian Asset Management LLC increased its stake in Eli Lilly and Company by 6.6% in the 1st quarter. Acadian Asset Management LLC now owns 36,897 shares of the company’s stock worth $28,699,000 after purchasing an additional 2,289 shares in the last quarter. Edgestream Partners L.P. increased its stake in Eli Lilly and Company by 13.8% in the 1st quarter. Edgestream Partners L.P. now owns 5,348 shares of the company’s stock worth $4,161,000 after purchasing an additional 649 shares in the last quarter. Covestor Ltd increased its stake in Eli Lilly and Company by 6.5% in the 1st quarter. Covestor Ltd now owns 296 shares of the company’s stock worth $230,000 after purchasing an additional 18 shares in the last quarter. Finally, Alley Investment Management Company LLC increased its stake in Eli Lilly and Company by 0.4% in the 1st quarter. Alley Investment Management Company LLC now owns 10,623 shares of the company’s stock worth $8,264,000 after purchasing an additional 38 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 4.9 %

Shares of Eli Lilly and Company stock opened at $746.20 on Friday. The firm has a market cap of $708.38 billion, a price-to-earnings ratio of 80.67, a P/E/G ratio of 2.82 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The stock has a 50-day simple moving average of $882.65 and a 200-day simple moving average of $870.38.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Citigroup lifted their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Bank of America dropped their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.